| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.27B | 3.15B | 2.93B | 2.61B | 2.31B | 2.09B |
| Gross Profit | 2.66B | 711.98M | 682.61M | 2.51B | 2.22B | 2.00B |
| EBITDA | 456.57M | 607.84M | 189.11M | 561.67M | 459.47M | 437.16M |
| Net Income | 107.36M | 255.61M | -21.67M | 273.14M | 190.63M | -672.13M |
Balance Sheet | ||||||
| Total Assets | 6.41B | 5.96B | 5.36B | 4.99B | 4.77B | 6.50B |
| Cash, Cash Equivalents and Short-Term Investments | 118.69M | 76.31M | 100.07M | 97.65M | 133.81M | 378.70M |
| Total Debt | 2.43B | 2.09B | 1.51B | 1.53B | 1.64B | 3.26B |
| Total Liabilities | 3.12B | 2.77B | 2.47B | 2.09B | 2.19B | 4.60B |
| Stockholders Equity | 3.12B | 3.07B | 2.78B | 2.81B | 2.52B | 1.90B |
Cash Flow | ||||||
| Free Cash Flow | -347.22M | -560.69M | 38.21M | 84.42M | 129.67M | 442.19M |
| Operating Cash Flow | 334.89M | 129.69M | 462.34M | 380.57M | 374.48M | 658.81M |
| Investing Cash Flow | -667.11M | -736.48M | -397.22M | -305.83M | 1.02B | -281.84M |
| Financing Cash Flow | 368.76M | 583.02M | -62.70M | -110.90M | -1.64B | -51.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $2.18B | 21.67 | 9.94% | 1.78% | 23.74% | -18.99% | |
70 Outperform | $1.86B | 17.23 | 5.57% | 1.64% | -22.96% | -59.35% | |
61 Neutral | $1.34B | 12.24 | 3.49% | ― | 4.58% | -61.50% | |
61 Neutral | $2.51B | -8.12 | -214.33% | ― | 3.93% | -42.22% | |
61 Neutral | $2.69B | -291.60 | -0.62% | ― | 13.39% | 90.55% | |
55 Neutral | $2.04B | -11.68 | -9.45% | ― | 10.14% | -182.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On December 2, 2025, Acadia Healthcare Company, Inc. released updated guidance for the fiscal year ending December 31, 2025. This announcement provides stakeholders with revised expectations for the company’s financial performance, potentially impacting investor decisions and market perceptions.
On November 7, 2025, Acadia Healthcare agreed to settle a securities litigation case in the U.S. District Court for the Middle District of Tennessee, involving the St. Clair County Employees’ Retirement System. The settlement, which amounts to $179 million, will be funded through insurance proceeds, cash on hand, and existing credit lines, and will not impact the company’s adjusted EBITDA or financial guidance. Acadia maintains a strong financial position with significant cash reserves and credit availability, ensuring its capacity for strategic investments.
Acadia Healthcare Company, Inc. announced the appointment of Todd Young as Chief Financial Officer, effective October 27, 2025. Young, who has previously held CFO roles at Elanco Animal Health and ACADIA Pharmaceuticals, will replace interim CFO Timothy Sides, who will return to his role as Senior Vice President, Operations Finance. The appointment is accompanied by a comprehensive employment agreement detailing Young’s compensation and benefits, including a substantial base salary, potential bonuses, and stock awards, reflecting the company’s commitment to strengthening its financial leadership.
Acadia Healthcare announced its participation in the Jefferies 2025 Healthcare Services Conference on September 29, 2025, where it provided preliminary guidance for 2026. The company expects a significant reduction in total capital expenditures by at least $300 million compared to 2025 and plans to add 500 to 700 beds in 2026. Additionally, Acadia reported a 1.3% growth in same facility patient days for the third quarter of 2025, indicating a positive trend in patient engagement. These developments suggest a strategic shift towards optimizing operational efficiency and expanding capacity, which could enhance Acadia’s market position and stakeholder value.